New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
04:55 EDTDHR, DHR, DHR, TEVA, TEVA, TEVA, GMED, GMED, GMED, RHHBY, RHHBY, RHHBY, MDCO, MDCO, MDCO, NVO, NVO, NVO, GILD, GILD, GILD, OMI, OMI, OMI, PKI, PKI, PKI, WCG, WCG, WCG, BDX, BDX, BDXGoldman to hold a conference
35th Annual Global Healthcare Conference to be held in Rancho Palos Verdes, California on June 10-12.
News For DHR;WCG;PKI;OMI;GILD;NVO;MDCO;RHHBY;GMED;TEVA;BDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 8, 2015
16:22 EDTTEVAOn The Fly: Closing Wrap
Subscribe for More Information
15:19 EDTRHHBYRoche says receives European approval for Avastin plus chemotherapy
Roche announced that the European Commission approved Avastin -- bevacizumab -- in combination with standard chemotherapy for the treatment of adult patients with persistent, recurrent or metastatic carcinoma of the cervix. The EU approval was based on the significant survival benefit in the pivotal GOG-0240 study, which showed that women who received Avastin plus chemotherapy had a statistically significant 26% reduction in the risk of death, representing a median improvement in survival of nearly four months, compared to women who received chemotherapy alone.
14:23 EDTTEVAAdditional bidders for Perrigo could emerge after Mylan offer, says Stifel
Subscribe for More Information
13:07 EDTTEVAMylan bid for Perrigo makes strategic sense, says JPMorgan
Subscribe for More Information
12:37 EDTTEVATeva downgraded to Hold from Buy at Standpoint Research
Subscribe for More Information
07:16 EDTTEVAMylan one of the cheapest names in Specialty Pharma, says JPMorgan
Subscribe for More Information
April 7, 2015
17:58 EDTGILDGilead submits NDA for investigational combination for treatment of HIV-1
Subscribe for More Information
16:00 EDTGILDOptions Update; April 7, 2015
Subscribe for More Information
15:44 EDTNVONovo Nordisk announces FDA accepts Tresiba, Ryzodeg resubmissions for review
Novo Nordisk announced that the U.S. FDA has accepted for review the Class II Resubmissions for Tresiba and Ryzodeg. To preserve the integrity of the ongoing DEVOTE trial, only a small team within Novo Nordisk has access to the data. This team has prepared the interim analysis for the Class II resubmission and will interact with the FDA during the review, on matters related to the interim analysis. As previously communicated, the result of an interim analysis carries a higher level of uncertainty than the final study results as this preliminary estimate is built on a substantially lower number of observations. Accordingly, the relative risk estimate derived from the interim analysis is thus only an indication of the final trial results. Novo Nordisk management does not have access to the results of the interim analysis. The trial is expected to be completed in the second half of 2016.
15:24 EDTTEVATeva price target raised to $75 from $64 at BMO Capital
BMO Capital raised its EPS estimates for Teva (TEVA) and increased its price target on the stock to $75 from $64 on account of the expected launch of a treatment for chorea associated with Huntingtonís disease in 3Q16 and a launch of a tardive dyskinesia drug in 3Q17 following the company's deal to buy Auspex (ASPX). The firm maintains its Outperform rating on Teva shares.
08:20 EDTWCGCowen expects managed care stocks to outperform following CMS release
Cowen expects managed care stocks to outperform today following the CMS release outlining better than expected Medicare Advantage rates for 2016. The firm also sees improved FFS growth rates, maintained coding intensity adjustment, and continued HRA payments. Publicly traded companies in the space include Aetna (AET), Cigna (CI), Health Net (HNT), Humana (HUM), and WellCare (WCG).
07:57 EDTWCGManaged care companies likely to rise on CMS news, says Oppenheimer
Subscribe for More Information
07:41 EDTWCG2016 MA rates positive for first time in seven years, says Deutsche Bank
Deutsche Bank notes that for the first time since 2009, Medicare Advantage rates will be positive after the Centers for Medicare and Medicaid Services announced yesterday that final 2016 rates will rise by 1.25%, representing a 220 basis points favorable swing from the preliminary proposed cut of 0.95%. Deutsche says the positive surprise is "somewhat tempered" by the more cautious view on Medicare cost trends provided by the CMS actuaries in the final 2016 rate announcement. The firm expects Humana (HUM), Health Net (HNT) and UnitedHealth (UNH), Aetna (AET) and Anthem (ANTM) to experience Medicare Advantage rate increases.
07:39 EDTWCGSome managed care stocks could be pressured by CMS decision, says Stifel
Subscribe for More Information
07:14 EDTRHHBYEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.
April 6, 2015
13:32 EDTBDXBecton Dickinson, Breakout Labs form strategic relationship
Breakout Labs, Peter Thielís philanthropic revolving fund for early-stage science and technology companies, and BD announced that they have established a strategic relationship to provide additional grant funding and professional expertise to qualifying Breakout Labs portfolio companies. Under the terms of the agreement, BD will periodically review Breakout Labsí portfolio for companies developing cutting-edge technologies that are relevant to the strategic interests of BDís Medical and Life Sciences business segments. Breakout Labs companies selected to participate will be given an unrestricted grant of up to $25,000 from BD, and assigned a business mentor responsible for providing guidance and connections to subject matter experts throughout the company.
07:57 EDTWCGLeerink healthcare services analyst holds analyst/industry conference call
Healthcare Services Analyst Gupte discusses the leverage Anthem likely has in its Pharmacy Benefit Manager (PBM) contract with Express Scripts and how it changes after the Catamaran-Optum Rx deal, the synergy potential for the deal between Catamaran and Optum Rx and the likelihood of Cigna-HS remaining with the newly merged Optum Rx-CTRX on an Analyst/Industry conference call to be held on April 6 at 2 pm.
07:36 EDTGILDGilead Q1 HCV revenue poised to beat expectations, says RBC Capital
After analyzing weekly prescription data, RBC Capital believes that Gilead's weekly hepatitis C prescriptions are tracking towards $3.5B-$3.6B of revenue from hepatitis C drugs for Q1, versus the consensus outlook of about $2.6B. The firm keeps an Outperform rating on Gilead.
05:56 EDTTEVATeva battles possible generic Copaxone competitors, Globes reports
A citizen's petition has been filed by Teva with the FDA against possible generic competition to its MS treatment Copaxone beginning in September, Globes reports. The FDA has previously ruled that it was "too early" to discuss the matter. Reference Link
April 5, 2015
14:43 EDTGILDActavis seeks FDA approval to market generic version of Gilead's Letairis
Actavis (ACT) on Friday, confirmed that it has filed an Abbreviated New Drug Application with the FDA seeking approval to market Ambrisentan Tablets, 5 mg and 10 mg. Actavis' ANDA product is a generic version of Gilead Science's (GILD) Letairis, which is a treatment for pulmonary arterial hypertension. Gilead Sciences and Royalty Pharma Collection Trust filed suit against Actavis on April 1, in the U.S. District Court for the District of Delaware seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of U.S. Patent number RE42,462. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis' ANDA for up to 30 months from the date the plaintiffs received notice of Actavis' ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities. Based on available information, Actavis believes it may be a "first applicant" to file an ANDA for the generic version of Letairis and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity. For the 12 months ending December 31, Letairis had global sales of approximately $595M, according to Gilead.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use